FLKS: Flex Pharma, Inc. - Summary | Jitta

Flex Pharma, Inc.

NASDAQ:FLKS

Notice
Stock data is unavailable or the company’s delisted.
Price
$11.80
Loss Chance
58.4%
0.24JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (10)
Recent Business Performance (40)
Financial Strength (10)
Return to Shareholders (0)
Competitive Advantage (4)
Jitta Signs
Recent Business PerformanceEarning decline 40.45% in the last year
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.24
100.00%
3.05
193.40%
Pharmaceuticals
4.44
8.42%
2.69
94.10%
5.18
35.59%
COMPANY DESCRIPTION
As of July 19, 2019, Flex Pharma, Inc. was acquired by Salarius Pharmaceuticals, LLC, in a reverse merger transaction. Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company’s lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.